Hoe 140 a new potent and long acting bradykinin‐antagonist: in vitro studies

Hoe 140 a new potent and long acting bradykinin‐antagonist: in vitro studies 1 Hoe 140 (d‐Arg‐(Hyp3, Thi5, d‐Tic7, Oic8)bradykinin) is a new bradykinin (BK)‐antagonist. It was tested in several in vitro assays and compared with d‐Arg‐(Hyp2, Thi5,8,d‐Phe7)BK. 2 In receptor binding studies in guinea‐pig ileum preparations, Hoe 140 showed an IC50 of 1.07 × 10−9mol l−1 and a KI value of 7.98 × 10−10 mol l−1. 3 In isolated organ preparations Hoe 140 and d‐Arg‐(Hyp2, Thi5,8, d‐Phe7)BK inhibited bradykinin‐induced contractions concentration dependently, with IC50‐values in the guinea‐pig ileum preparation of 1.1 × 10−8 mol l−1 and 3 × 10−5 mol l−1, respectively. pA2 values in this tissue were 8.42 and 6.18, respectively. In the rat uterus preparation the IC50 value was 4.9 × 10−9 mol l−1 for Hoe 140. d‐Arg‐(Hyp2, Thi5,8, d‐Phe7)BK showed an IC50 of 4.0 × 10−6 mol l−1. The IC50 values in the guinea‐pig isolated pulmonary artery were 5.4 × 10−9 mol l−1 and 6.4 × 10−6 mol l−1, respectively. In the rabbit aorta no inhibitory effects on Des‐Arg9‐BK induced contractions were observed. 4 In cultured bovine endothelial cells, Hoe 140 antagonized (IC50 = 10−8 mol l−1) bradykinin‐induced endothelium‐derived relaxing factor (EDRF) release and the bradykinin‐induced increase in cytosolic free calcium (IC50 = 10−9 mol l−1). 5 Hoe 140 (10−7 mol l−1) totally suppressed the bradykinin‐induced (10−8 to 10−4mol l−1) prostacyclin (PGI2) release from cultured endothelial cells of bovine aorta. d‐Arg‐(Hyp2, Thi5,8, d‐Phe7)BK (10−7 mol l−1) showed a weaker antagonism. 6 Taken together these results show that Hoe 140 is a highly potent bradykinin antagonist. It was two to three orders of magnitude more potent than d‐Arg‐(Hyp2, Thi5,8, d‐Phe7)BK. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png British Journal of Pharmacology Wiley

Hoe 140 a new potent and long acting bradykinin‐antagonist: in vitro studies

Loading next page...
 
/lp/wiley/hoe-140-a-new-potent-and-long-acting-bradykinin-antagonist-in-vitro-J7ApWPAW2I
Publisher
Wiley
Copyright
1991 British Pharmacological Society
ISSN
0007-1188
eISSN
1476-5381
DOI
10.1111/j.1476-5381.1991.tb12248.x
Publisher site
See Article on Publisher Site

Abstract

1 Hoe 140 (d‐Arg‐(Hyp3, Thi5, d‐Tic7, Oic8)bradykinin) is a new bradykinin (BK)‐antagonist. It was tested in several in vitro assays and compared with d‐Arg‐(Hyp2, Thi5,8,d‐Phe7)BK. 2 In receptor binding studies in guinea‐pig ileum preparations, Hoe 140 showed an IC50 of 1.07 × 10−9mol l−1 and a KI value of 7.98 × 10−10 mol l−1. 3 In isolated organ preparations Hoe 140 and d‐Arg‐(Hyp2, Thi5,8, d‐Phe7)BK inhibited bradykinin‐induced contractions concentration dependently, with IC50‐values in the guinea‐pig ileum preparation of 1.1 × 10−8 mol l−1 and 3 × 10−5 mol l−1, respectively. pA2 values in this tissue were 8.42 and 6.18, respectively. In the rat uterus preparation the IC50 value was 4.9 × 10−9 mol l−1 for Hoe 140. d‐Arg‐(Hyp2, Thi5,8, d‐Phe7)BK showed an IC50 of 4.0 × 10−6 mol l−1. The IC50 values in the guinea‐pig isolated pulmonary artery were 5.4 × 10−9 mol l−1 and 6.4 × 10−6 mol l−1, respectively. In the rabbit aorta no inhibitory effects on Des‐Arg9‐BK induced contractions were observed. 4 In cultured bovine endothelial cells, Hoe 140 antagonized (IC50 = 10−8 mol l−1) bradykinin‐induced endothelium‐derived relaxing factor (EDRF) release and the bradykinin‐induced increase in cytosolic free calcium (IC50 = 10−9 mol l−1). 5 Hoe 140 (10−7 mol l−1) totally suppressed the bradykinin‐induced (10−8 to 10−4mol l−1) prostacyclin (PGI2) release from cultured endothelial cells of bovine aorta. d‐Arg‐(Hyp2, Thi5,8, d‐Phe7)BK (10−7 mol l−1) showed a weaker antagonism. 6 Taken together these results show that Hoe 140 is a highly potent bradykinin antagonist. It was two to three orders of magnitude more potent than d‐Arg‐(Hyp2, Thi5,8, d‐Phe7)BK.

Journal

British Journal of PharmacologyWiley

Published: Mar 1, 1991

References

  • Kinins act on B 1 or B 2 receptors to release conjointly endothelium‐derived relaxing factors and prostacyclin from bovine aortic cells
    D'ORLÉANS‐JUSTE, D'ORLÉANS‐JUSTE; NUCCI, NUCCI; VANE, VANE
  • Antagonists of B 2 bradykinin receptors
    STERANKA, STERANKA; FARMER, FARMER; BURCH, BURCH
  • Bradykinin‐antagonists: Therapeutic perspectives
    TAYLOR, TAYLOR; DeFEUDIS, DeFEUDIS; MOREAU, MOREAU
  • Calcium homeostasis in intact lymphocytes: Cytoplasmic free calcium monitored with a new intracellularly trapped fluorescent indicator
    TSIEN, TSIEN; POZZAN, POZZAN; RINK, RINK

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off